

## Evaluation of Blood-Perilymph Barrier in Ears with Endolymphatic Hydrops

Journal:	<i>Acta Oto-Laryngologica</i>
Manuscript ID	SOTO-2021-0322
Manuscript Type:	Regular
Classification Scheme:	inner ear
Keywords:	MRI, endolymphatic hydrops, signal intensity

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 **Evaluation of the blood–perilymph barrier in ears with endolymphatic hydrops**

2

3 **Running head:** Blood–perilymph barrier and endolymphatic hydrops

4

5 **Address for correspondence:**

6

For Peer Review Only

## 7 Abstract

8 **Background:** Otological diseases including Meniere's disease (MD) involve  
9 endolymphatic hydrops (EH), which can be visualized by magnetic resonance imaging  
10 (MRI) with gadolinium contrast agents, but the temporal changes of contrast in the  
11 inner ear have not been evaluated.

12 **Objectives:** We investigated the permeability of the blood–perilymph barrier (BPB) in  
13 ears with EH to evaluate the severity of the inner ear disturbances.

14 **Materials and methods:** The study included 32 ears from 16 patients with EH or  
15 related diseases who underwent MRI. The permeability of the BPB was assessed by the  
16 signal–intensity ratio (SIR) at four time points: before and at 10 minutes, 4 hours, and  
17 24 hours after administration of gadolinium for assessing EH.

18 **Results:** Cochlear EH was found in 25 of the 32 ears, and vestibular EH in 11. The rate  
19 of EH was significantly higher in symptomatic ears; however, the existence of EH was  
20 not related to SIR values. Nevertheless, SIR values in the basal turn were significantly  
21 higher 4 and 24 hours after injection of gadolinium in patients aged  $\geq 50$  years.

22 **Conclusion and significance:** Higher SIR values observed in older patients with EH  
23 indicate severe disturbances of the BPB in the cochlea, which may account for  
24 intractable inner ear disturbances in older patients.

25 **Key words:** MRI—endolymphatic hydrops—signal intensity.

## 26 Introduction

27 Meniere's disease (MD) is related to pathological endolymphatic hydrops (EH) of  
28 the inner ear. Gadolinium (Gd)-enhanced magnetic resonance imaging (MRI) is used to  
29 visualize EH in living humans [1,2]. Intravenously injected Gd slowly enters the

1  
2  
3  
4  
5 30 perilymphatic space but not the endolymphatic space and the difference in concentration  
6  
7  
8 31 between these two spaces is used to identify EH [3].  
9

10 32 The mechanism responsible for the barrier function in the inner ear as provided by  
11  
12 33 the blood–perilymph barrier (BPB) can be explained as follows. The maintenance of  
13  
14 34 inner ear fluid homeostasis provides a barrier function between the vascular system and  
15  
16  
17 35 the inner ear fluid. Morphologically similar to cells of the blood–brain barrier (BBB),  
18  
19 36 endothelial cells in the BPB lack fenestrations and their lumen is sealed with tight  
20  
21 37 junctions and adherens junctions. Pericytes and perivascular resident macrophage-like  
22  
23  
24 38 melanocytes are in intimate contact with endothelial cells and add multiple basement  
25  
26 39 membrane layers, which tightly regulate the exchange between the blood and interstitial  
27  
28 40 fluid [4].  
29

30 41 Recent data provide direct evidence of the impaired function of the BPB in MD.  
31  
32  
33 42 MD is associated with deteriorating BPB, as evaluated with MRI postcontrast  
34  
35 43 measurements of signal intensity. Specific ultrastructural changes in capillaries  
36  
37 44 constituting the BPB have been identified in utricles removed during surgery from  
38  
39 45 patients with MD [4]. The increased prevalence and severity of EH with the duration of  
40  
41  
42 46 MD indicate that hydrops is a progressive degenerative phenomenon. Frequent  
43  
44 47 abnormalities in the vestibule and cochlea have been noted in some histopathological  
45  
46  
47 48 investigations [5].  
48

49 49 The mechanism of MD attacks is unknown. Foster et al. [6] reported that the unique  
50  
51 50 characteristics of the attacks can be explained by the differential sensitivity of the inner  
52  
53  
54 51 ear tissues to transient ischaemia. In such attacks, the sensory tissues are vulnerable to  
55  
56 52 hours-long ischaemia or reperfusion injury, and the stria vascularis is vulnerable to  
57  
58 53 ischaemia because of its high metabolic rate. Foster et al. also noted an association  
59  
60

1  
2  
3  
4  
5 54 between EH and vascular risk factors for intracerebral ischaemia. Therefore, changes in  
6  
7  
8 55 vascular permeability of the inner ear may be closely involved in MD attacks and the  
9  
10 56 development of EH. To evaluate the role in MD attacks of BPB permeability and the  
11  
12 57 severity of the inner ear disturbances, we examined the signal intensity and contrast  
13  
14 58 effect in multiple MRI images of the inner ear.

## 17 18 59 **Methods**

### 19 20 21 60 ***Patients***

22  
23 61 A total of 32 ears in 16 patients diagnosed with MD or EH-related diseases who  
24  
25 62 underwent otological examination and MRI were recruited to the study between 2018  
26  
27 63 and 2020. The diagnoses of patients with MD were based on the new international  
28  
29 64 consensus diagnostic criteria for MD [7].

### 30 31 32 33 65 ***Pure-tone audiometry***

34  
35 66 Pure-tone audiometry was performed before the MRI study using an audiometer  
36  
37 67 (Model AA-78; Rion, Tokyo, Japan) in a sound-insulated chamber. If the patient did not  
38  
39 68 respond to the maximum level of sound, 5 dB was added to each threshold. The average  
40  
41 69 hearing level was expressed as the average score at three frequencies (500, 1,000, and  
42  
43 70 2,000 Hz).

### 44 45 46 47 71 ***MRI***

48  
49 72 MRI evaluation used a 3-Tesla scanner (Magnetom Skyra; Siemens, Erlangen,  
50  
51 73 Germany) equipped with a receive-only, 32-channel, phased-array coil. MRI was  
52  
53 74 performed before, and 10 minutes, 4 hours, and 24 hours after intravenous  
54  
55 75 administration of a standard dose of Gd hydrate (gadobutrol 0.1 mmol/kg; Gadovist;  
56  
57 76 Bayer AG, Leverkusen, Germany). All patients underwent heavily T<sub>2</sub>-weighted (hT<sub>2</sub>W)

1  
2  
3  
4  
5 77 MR cisternography (MRC) for anatomical reference of the fluid space and hT2W-three-  
6  
7 78 dimensional (3D) fluid-attenuated inversion recovery MRI (3D-FLAIR) for evaluation  
8  
9  
10 79 of labyrinthine fluid alterations in 7 minutes. The inversion time ( $T_1$ ) was 2250 ms after  
11  
12 80 MRC images using a variable flip angle 3D turbo spin–echo technique, sampling  
13  
14 81 perfection with application-optimized contrasts using different flip angle evolutions  
15  
16 82 (SPACE) and the repetition time was 9000 ms. The presence of EH was investigated  
17  
18 83 using a hybrid of a reversed image of the positive endolymph signal and native image of  
19  
20 84 the positive perilymph signal, a hybrid of the reversed image of MRC, positive  
21  
22 85 perilymph signal by heavily  $T_2$ -weighted (h $T_2$ W) 3D-FLAIR, and 3D-real inversion  
23  
24 86 recovery (IR) sequences. The detailed parameters of 3D-real IR were reported  
25  
26 87 previously [8].

27  
28  
29  
30 88 At least two radiologists with more than 20 years of experience who were blinded to  
31  
32 89 the clinical symptoms classified the degree of EH in the cochlea and vestibule into one  
33  
34 90 of three groups: none, mild, or significant, according to previously described criteria  
35  
36 91 [9]. Example images of EH in the cochlea are shown in Figure 1.

#### 92 ***Evaluation of Gd contrast effects***

93 The contrast effects on the cochlear and vestibular fluid were evaluated semi-  
94 quantitatively, as reported previously in patients with sudden deafness [10]. The signal–  
95 intensity ratio (SIR) was measured three times, and the average SIR value was  
96 calculated for each ear. The signal intensities in the basal turn of each affected and  
97 unaffected cochlea were quantified as follows. Morphological distortion of the scala  
98 tympani because of enlargement of the scala media (EH) is less than that of the scala  
99 vestibuli. Contouring of the scala tympani in the basal turn of the cochlea is easy and  
100 stable regardless of the degree of EH. Therefore, measurements of the lymph fluid

1  
2  
3  
4  
5  
6 101 signal were performed for the scala tympani in the basal turn of the cochlea. For the  
7  
8 102 scala tympani region of interest (ROI), the slice was selected at least 3 slices below the  
9  
10 103 centre slice on which the cochlear modiolus appeared largest. For quantitative  
11  
12 104 evaluation, the SIR between the signals of the scala tympani and cerebellum was  
13  
14 105 measured on 3D-real IR images. The ROI for the cerebellum was set as a circle with a  
15  
16 106 diameter of 10 mm in the ipsilateral cerebellar white matter on the MRC images. The  
17  
18 107 ROI for the scala tympani was drawn manually on the MRC images. ROIs were copied  
19  
20 108 and pasted onto 3D-real IR images (Figure 2). Using the signal value of the cerebellar  
21  
22 109 hemisphere as a control, each SIR was calculated as the signal intensity of the  
23  
24 110 ROI/signal intensity of the cerebellar hemisphere [10]. The results of simple SIR  
25  
26 111 measurements have been reported to correlate well with those based on a quantitative  
27  
28 112 method [8]. Gd excretion rate was calculated using  $(\text{SIR 4 hours} - \text{SIR 24 hours}) / \text{SIR 4}$   
29  
30 113 hours.

#### 35 114 ***Ethics review***

36  
37  
38 115 The study was approved by the Ethics Review Committee of \*\*\*\*\* (No. 2018–  
39  
40 116 0218).

#### 42 117 ***Statistical analysis***

43  
44  
45 118 IBM SPSS Statistics software (version 27, IBM Corp., Armonk, NY) was used for  
46  
47 119 statistical analyses. The Mann–Whitney *U* test, Fisher’s exact test, and one-way  
48  
49 120 analysis of variance followed by the post hoc Bonferroni test were used, as appropriate,  
50  
51 121 for comparisons. The significance level was set at 5%.

## 122 **Results**

123 The study population included 6 women and 10 men (average age 50.2 years; range  
124 26–76 years) (Table 1). The diagnoses of the 16 patients were unilateral definite MD ( $n$   
125 = 3), probable MD ( $n = 1$ ), delayed EH ( $n = 4$ ) and other ( $n = 8$ ). Case 7 was diagnosed  
126 as bilateral definite MD. Bilateral MD was defined as confirmed MD in one ear, with  
127 the opposite ear having inner-ear symptoms combined with documented hearing loss.  
128 The patients categorized as having the “other” diagnosis did not meet the new criteria  
129 because of the duration of episodes of vertigo and the level of their pure-tone  
130 thresholds. However, they were diagnosed with probable or possible MD according to  
131 the 1995 American Academy of Otolaryngology-Head and Neck Surgery guidelines  
132 [11].

133 EH was present in the cochlea in 30 of 32 ears (94%), and significant EH was  
134 present in 25 of 32 ears (78%). EH was present in the vestibule in 15 of 32 ears (47%),  
135 and significant EH was present in 11 of 32 ears (34%). Table 2 shows the distribution of  
136 ears with EH in the cochlea and vestibule. The degree of EH was significant in both the  
137 cochlea and vestibule in the symptomatic ear. The average duration of disease in all  
138 cases was 103.1 months (range 0–360 months). The degree of EH did not differ  
139 significantly according to age and duration of disease (Figure 3A and B).

140 The changes in the SIR values for the cochlear basal turn, before, immediately after,  
141 and 4 hours and 24 hours after intravenous Gd injection are shown in Figure 4A–C.  
142 Figure 4A shows the results for patients aged  $< 50$  years versus  $\geq 50$  years. Figure 4B  
143 shows the data for the patients grouped according to the presence or absence of EH.  
144 Figure 4C shows the data for the patients grouped according to the average hearing  
145 level,  $< 40$  dB and  $\geq 40$  dB. The highest SIR values in all groups were obtained 4 hours



1  
2  
3  
4  
5  
6 146 after contrast. The SIR value was significantly higher in the older group at 4 hours  
7  
8 147 (mean, 29.2 vs 15.9;  $p < 0.001$ ) and 24 hours (mean, 19.2 vs 9.0;  $p < 0.001$ ) after  
9  
10 148 contrast (Figure 4A). The excretion rate was calculated as 43.2% in patients aged <50  
11  
12 149 years and 34.4% in those aged  $\geq 50$  years, 42.7% in the absence of EH and 37.0% in the  
13  
14 150 presence of EH, 36.7% in those with average hearing level <40 dB and 38.0% in those  
15  
16 151 with  $\geq 40$  dB, respectively. No significant differences were found for the other  
17  
18 152 comparisons.  
19  
20  
21  
22

### 23 153 **Discussion**

24  
25 154 This is the first study to compare the inner ear findings obtained using enhanced  
26  
27 155 MRI at four time points up to 24 hours after Gd administration. We found that patients  
28  
29 156 aged  $\geq 50$  years with EH in the cochlea and vestibule showed greater vascular  
30  
31 157 permeability of the BPB than younger patients. The excretion rate of contrast media did  
32  
33 158 not differ significantly between older and younger patients. We found no relationship  
34  
35 159 between SIR values and the presence of EH or hearing level.  
36  
37  
38

39 160 In animal studies, inflammation produces changes in the BPB that lead to increased  
40  
41 161 vascular permeability. It is thought that a compromised BPB would lead to hearing  
42  
43 162 impairment through the loss of the endocochlear potential [12]. The BBB limits entry of  
44  
45 163 blood-derived products, pathogens, and cells into the brain, and the BPB functions  
46  
47 164 similarly in the inner ear. BBB breakdown is an early event in the aging human brain  
48  
49 165 that begins in the hippocampus and may contribute to cognitive impairment [13]. BBB  
50  
51 166 permeability, expressed as a ratio of infarct permeability to contralateral permeability, is  
52  
53 167 greatest at 6–48 hours after the onset of acute ischaemic stroke. These findings suggest  
54  
55 168 that the permeability of the BBB is elevated continuously following acute ischaemic  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 169 stroke. Moreover, the 'glymphatic system' is hypothesized to be a waste clearance  
6  
7 170 system of the cerebrospinal fluid through the perivascular and interstitial spaces in the  
8  
9  
10 171 brain. MRI has also been used to evaluate glymphatic function primarily using Gd-  
11  
12 172 based contrast agents as tracers [14]. Glaucoma, normal pressure hydrocephalus, and  
13  
14 173 MD are consistent in their disturbance of fluid homeostasis [15]. In addition, both  
15  
16 174 glaucoma and normal-pressure hydrocephalus are presumed to be dysfunctions of the  
17  
18 175 glymphatic system, which is a waste excretion mechanism [14]. Therefore, MD may be  
19  
20 176 caused not only by abnormalities in the BPB but also by abnormalities in the waste  
21  
22 177 excretion mechanism of the inner ear. This study demonstrated that the excretion rate  
23  
24 178 was delayed in the EH group and the group >50 years old, by comparing 4 and 24 hours  
25  
26 179 post-contrast. Our results suggest that assessing the dysfunction of excretory function is  
27  
28 180 the key to the discovery of new biomarkers for MD.  
29  
30  
31  
32

33 181 Similar to these findings in the BBB, it is also possible that vascular permeability  
34  
35 182 increases with age in the BPB in the inner ear. The function of the BPB has been  
36  
37 183 reported. The rate of transfer of some medicines, such as gentamicin (molecular weight,  
38  
39 184 477.6) from the blood into the perilymph is faster than from the blood into the  
40  
41 185 endolymph. The rate of Gd-diethylenetriamine pentaacetic acid penetration into the  
42  
43 186 BPB is slow, with a peak concentration occurring 4 hours after administration, which  
44  
45 187 suggests the presence of a tight barrier between the perilymph and blood [3]. In healthy  
46  
47 188 people, cochlear fluid is enhanced most intensely 4 hours after the injection [3]. The  
48  
49 189 optimal timing of contrast enhancement in patients with suspected MD remains unclear,  
50  
51 190 but an evaluation of EH is possible 3.5–4.5 hours after contrast administration [8].  
52  
53  
54  
55

56 191 The SIR in the cochlea and brainstem or cerebellar hemisphere has been used to  
57  
58 192 evaluate the BPB. The SIR increases more in symptomatic ears than in asymptomatic  
59  
60

1  
2  
3  
4  
5  
6 193 ears at 4 hours after intravenous Gd injection used in combination with hT2W-3D-  
7  
8 194 FLAIR MRI [16]. Gd movement into the inner ear from the blood circulation is greater  
9  
10 195 in hydropic ears than in normal ears [17]. A recent study showed that the combination  
11  
12 196 of perilymphatic enhancement and EH in patients suspected of having MD increases the  
13  
14 197 positive predictive value for the definite diagnosis of MD [18].

15  
16  
17 198 In this study, SIR values did not differ significantly between ears with and without  
18  
19 199 EH. One limitation of this study is that we focused on the presence or absence of EH in  
20  
21 200 ears with various types of otological diseases. Okazaki et al. [19] observed cochlear and  
22  
23 201 vestibular EH in 66% and 41% of affected ears with sudden sensorineural hearing loss  
24  
25 202 (SSNHL), respectively. In that study, cochlear and vestibular EH were also detected in  
26  
27 203 52% and 38% of the unaffected ears with SSNHL, respectively. These findings were  
28  
29 204 deemed to indicate secondary EH. We found that the degree of EH was greater in  
30  
31 205 symptomatic ears. However, EH alone is insufficient to cause symptomatic MD and  
32  
33 206 vascular risk factors should be studied as possible cofactors [6]. Older people have a  
34  
35 207 higher risk of vascular disease, which also increases their risk of developing inner ear  
36  
37 208 diseases, including SSNHL [20].

38  
39  
40 209 The present study revealed a difference in vascular permeability at the BPB  
41  
42 210 between older and younger patients with EH. Repeated evaluations using MRI are not  
43  
44 211 applied to all patients with MD, and the number of patients enrolled in the study was  
45  
46 212 small. However, such evaluation using enhanced MRI may provide important  
47  
48 213 information for elucidating the role of the BPB in the pathophysiology of MD.

49  
50  
51 214 A limitation of this study is that we included only patients with EH. It would be  
52  
53 215 more interesting to include a comparison with a control group.  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 216 In conclusion, higher SIR values were observed in older patients with EH and the  
6  
7 217 excretion rate was delayed in older patients and in ears with EH. A detailed  
8  
9  
10 218 understanding of the signals that indicate a healthy BPB and the factors that promote  
11  
12 219 fluctuations in BPB permeability in disease states will be key to elucidating the disease  
13  
14 220 mechanisms and to identifying potential targets for diagnostics and therapeutic  
15  
16 221 modulation of BPB.  
17  
18  
19

20 222 **Disclosure statement**  
21

22 223 The authors have no funding, financial relationships or conflicts of interest to  
23  
24 224 disclose.  
25  
26

27 225  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

226 **References**

- 227 [1] Nakashima T, Pyykkö I, Arroll MA, et al. Ménière's disease. *Nat Rev Dis Primers*.  
228 2016;2:16028.
- 229 [2] Nakashima T, Naganawa S, Sugiura M, et al. Visualization of endolymphatic  
230 hydrops in patients with Ménière's disease. *Laryngoscope*. 2007;117:415–420.
- 231 [3] Naganawa S, Komada T, Fukatsu H, et al. Observation of contrast enhancement in  
232 the cochlear fluid space of healthy subjects using a 3D-FLAIR sequence at 3 Tesla.  
233 *Eur Radiol*. 2006;16:733–737.
- 234 [4] Glueckert R, Chacko LJ, Rask-Andersen H, et al. Anatomical basis of drug delivery  
235 to the inner ear. *Hear Res*. 2018;368:1027.
- 236 [5] Fiorino F, Pizzini FB, Beltramello A, et al. Progression of endolymphatic hydrops  
237 in Ménière's disease as evaluated by magnetic resonance imaging. *Otol Neurotol*.  
238 2011;32:1152–1157.
- 239 [6] Foster CA, Breeze RE. The Ménière attack: An ischemia/reperfusion disorder of  
240 inner ear sensory tissues. *Med Hypotheses*. 2013;81:1108–1115.
- 241 [7] Lopez-Escamez JA, Carey J, Chung W-H, et al. Diagnostic criteria for Ménière's  
242 disease. *J Vestib Res*. 2015;25:1–7.
- 243 [8] Naganawa S, Yamazaki M, Kawai H, et al. Visualization of endolymphatic hydrops  
244 in Ménière's disease with single-dose intravenous gadolinium-based contrast media  
245 using heavily T<sub>2</sub>-weighted 3D-FLAIR. *Magn Reson Med Sci*. 2010;9:237–242.
- 246 [9] Nakashima T, Naganawa S, Pyykkö I, et al. Grading of endolymphatic hydrops  
247 using magnetic resonance imaging. *Acta Otolaryngol Suppl*. 2009:5–8.

- 1  
2  
3  
4  
5  
6 248 [10] Yang C-J, Yoshida T, Sugimoto S, et al. Lesion-specific prognosis by magnetic  
7  
8 249 resonance imaging in sudden sensorineural hearing loss. *Acta Otolaryngol.*  
9  
10 250 2021;141:5–9.  
11  
12 251 [11] Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation  
13  
14 252 of therapy in Ménière's disease. American Academy of Otolaryngology–Head and  
15  
16 253 Neck Foundation, Inc. *Otolaryngol Head Neck Surg.* 1995;113:181–185.  
17  
18  
19 254 [12] Hirose K, Li SZ. The role of monocytes and macrophages in the dynamic  
20  
21 255 permeability of the blood–perilymph barrier. *Hear Res.* 2019;374:49–57.  
22  
23  
24 256 [13] Montagne A, Barnes SR, Sweeney MD, et al. Blood–brain barrier breakdown in the  
25  
26 257 aging human hippocampus. *Neuron.* 2015;85:296–302.  
27  
28  
29 258 [14] Taoka T, Naganawa S. Glymphatic imaging using MRI. *J Magn Reson Imaging.*  
30  
31 259 2020;51:11–24.  
32  
33 260 [15] Nakashima T, Sone M, Teranishi M, et al. A perspective from magnetic resonance  
34  
35 261 imaging findings of the inner ear: Relationships among cerebrospinal, ocular and  
36  
37 262 inner ear fluids. *Auris Nasus Larynx.* 2012;39:345–355.  
38  
39  
40 263 [16] Sano R, Teranishi M, Yamazaki M, et al. Contrast enhancement of the inner ear in  
41  
42 264 magnetic resonance images taken at 10 minutes or 4 hours after intravenous  
43  
44 265 gadolinium injection. *Acta Otolaryngol.* 2012;132:241–246.  
45  
46  
47 266 [17] Tagaya M, Yamazaki M, Teranishi M, et al. Endolymphatic hydrops and blood–  
48  
49 267 labyrinth barrier in Ménière's disease. *Acta Otolaryngol.* 2011;131:474–479.  
50  
51  
52 268 [18] van Steekelenburg JM, van Weijnen A, de Pont LMH, et al. Value of  
53  
54 269 endolymphatic hydrops and perilymph signal intensity in suspected Ménière  
55  
56 270 disease. *Am J Neuroradiol.* 2020;41:529–534.  
57  
58  
59  
60

- 1  
2  
3  
4  
5 271 [19] Okazaki Y, Yoshida T, Sugimoto S, et al. Significance of endolymphatic hydrops  
6  
7 272 in ears with unilateral sensorineural hearing loss. *Otol Neurotol.* 2017;38:1076–  
8  
9 273 1080.  
10  
11  
12 274 [20] Yoshida T, Sone M, Kitoh R, et al. Idiopathic sudden sensorineural hearing loss  
13  
14 275 and acute low-tone sensorineural hearing loss: A comparison of the results of a  
15  
16 276 nationwide epidemiological survey in Japan. *Acta Otolaryngol.* 2017;137:S38–S43.  
17  
18  
19 277  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 278 **Figure legends**  
6

7  
8 279 **Figure 1.** Example images of endolymphatic hydrops (EH) in the cochlea. Images were  
9  
10 280 obtained using a hybrid of the reversed image of the positive endolymph signal and the  
11  
12 281 native image of the positive perilymph signal and acquired 4 hours after intravenous  
13  
14 282 administration of single-dose gadolinium-based contrast material. The endolymphatic  
15  
16 283 space is observed as the black area. Right, significant EH in the cochlea (arrows). Left,  
17  
18 284 no EH in the cochlea.  
19

20  
21 285 **Figure 2.** Example images for the calculation of the region of interest (ROI) on 3D-real  
22  
23 286 inversion recovery (IR) sequences. We drew the shape of each basal turn of the cochlea  
24  
25 287 for the ROI on the SPACE sequence, then copied the shapes to draw the ROI on 3D-real  
26  
27 288 IR sequences (dotted line). (A) before enhancement, (B) 10 minutes after, and (C) 4  
28  
29 289 hours and (D) 24 hours after enhancement using the signal value of the cerebellar  
30  
31 290 hemisphere in the drawn circle as a control (E). The image was obtained from a patient  
32  
33 291 with significant endolymphatic hydrops. SPACE, sampling perfection with application-  
34  
35 292 optimized contrasts using different flip angle evolutions.  
36  
37

38  
39 293 **Figure 3.** (A) Comparison of the degree of EH in the cochlea according to age. (B)  
40  
41 294 Comparison of the degree of EH in the cochlea according to the duration of the disease.  
42  
43

44 295 **Figure 4.** Changes in mean SIR values of the cochlear basal turn before, immediately  
45  
46 296 after, and 4 hours and 24 hours after intravenous gadolinium injection. SIR was  
47  
48 297 measured three times, and the average SIR value was calculated for each ear. The  
49  
50 298 highest SIR values in all groups were obtained 4 hours after contrast. (A) Data are  
51  
52 299 presented according to age group <50 years and  $\geq$ 50 years. (B) Data are presented  
53  
54 300 according to the presence or absence of endolymphatic hydrops. (C) Data are presented  
55  
56 301 according to the average hearing level <40 dB and  $\geq$ 40 dB. PTA, pure-tone audiometry.  
57  
58  
59  
60



Table 1. Patients' clinical characteristics.

Case no.	Gender	Age(years)	Side	diagnosis	Average Hearing level (dB)	EH		SIR		Excretion rate (%)	Time from onset of symptoms(months)
						Cochlea	Vestibule	4 h	24 h		
1	M	27	Right	–	20.0	significant	no	6.6	3.4	48.6	–
			Left	DEH	66.7	significant	significant	10.9	4.6	57.5	168
2	M	37	Right	–	8.3	significant	no	15.0	7.4	50.9	–
			Left	Definite MD	46.7	significant	significant	26.8	8.4	68.5	156
3	M	37	Right	DEH	68.3	significant	significant	21.3	16.3	23.3	72
			Left	–	10.0	mild	no	28.2	26.0	7.9	–
4	F	76	Right	Fluctuated HL	66.7	significant	significant	25.1	12.0	52.1	36
			Left	–	10.0	no	no	32.5	12.4	61.9	–
5	M	35	Right	SNHL	105.0	significant	no	8.9	4.3	52.3	132
			Left	Fluctuated HL	61.7	significant	no	17.3	9.4	45.8	132
6	M	67	Right	Probable MD	41.7	significant	mild	26.2	18.0	31.3	204
			Left	–	8.3	no	no	24.8	20.4	17.6	–
7	M	55	Right	Definite MD	70.0	significant	significant	43.2	17.2	60.1	84
			Left	Definite MD	65.0	significant	significant	44.5	29.8	33.2	84
8	M	26	Right	Fluctuated HL	11.7	significant	no	12.8	5.5	56.8	36
			Left	Fluctuated HL	20.0	significant	no	12.7	5.2	59.1	1
9	F	63	Right	Fluctuated HL	70.0	significant	no	17.0	16.9	0.5	300
			Left	Fluctuated HL	45.0	mild	no	17.8	24.7	-38.5	1
10	M	56	Right	DEH	28.3	significant	significant	26.4	19.6	25.8	16
			Left	SNHL	86.7	significant	mild	43.8	29.8	32.0	300
11	F	32	Right	–	8.3	significant	no	11.2	5.8	48.6	–
			Left	Definite MD	30.0	significant	significant	15.3	4.9	68.0	6
12	F	72	Right	Fluctuated HL	48.3	mild	no	23.6	16.8	29.0	15
			Left	SNHL	86.7	significant	significant	39.1	21.8	44.2	96
13	F	75	Right	–	18.3	mild	no	29.2	23.7	18.8	–
			Left	Fluctuated HL	51.7	significant	no	28.2	18.8	33.3	10
14	M	44	Right	Fluctuated HL	16.7	significant	significant	17.3	13.5	22.0	24
			Left	Fluctuated HL	15.0	significant	mild	14.9	12.6	15.0	0
15	F	40	Right	SNHL	103.3	significant	no	17.6	10.1	42.9	240
			Left	Fluctuated HL	6.7	significant	mild	17.0	6.9	59.3	1
16	M	61	Right	DEH	56.7	significant	significant	24.0	11.1	53.7	360
			Left	–	21.7	mild	no	22.0	13.7	37.8	–

EH: Endolymphatic hydrops; SIR: signal intensity ratio; DEH: delayed endolymphatic hydrops; MD: Meniere's disease; HL: hearing loss; SNHL: sensorineural hearing loss

Excretion rate=(SIR 4h - 24 h)/SIR 4h

**TABLE 2.** Numbers and severity of EH in symptomatic and asymptomatic ears

Symptoms	Cochlea			Vestibule		
	Significant	Mild	None	Significant	Mild	None
Yes	21*	2	0	11*	3	9
No	4	3	2*	0	1	8*

EH: endolymphatic hydrops; symptoms: vestibular or cochlear symptom-related EH

\* $p < 0.05$  with versus (yes) without (no) symptoms (Fisher's exact test).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



Figure 1

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 2





Figure 3a

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



B

Figure 3b




Figure 4a

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 4b






Figure 4c